AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) – FBR & Co issued their FY2021 EPS estimates for shares of AVEO Pharmaceuticals in a research note issued on Thursday, Zacks Investment Research reports. FBR & Co analyst V. Bernardino forecasts that the biopharmaceutical company will post earnings of ($0.06) per share for the year. FBR & Co has a “Outperform” rating and a $3.00 price objective on the stock.

COPYRIGHT VIOLATION NOTICE: “AVEO Pharmaceuticals, Inc. (AVEO) to Post FY2021 Earnings of ($0.06) Per Share, FBR & Co Forecasts” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/04/21/equities-analysts-offer-predictions-for-aveo-pharmaceuticals-inc-s-fy2021-earnings-aveo-updated-updated.html.

Separately, Zacks Investment Research downgraded shares of AVEO Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, March 27th.



AVEO Pharmaceuticals (NASDAQ:AVEO) traded down 1.6780% during midday trading on Friday, hitting $0.5801. 469,257 shares of the stock were exchanged. The firm has a 50 day moving average of $0.72 and a 200-day moving average of $0.68. The stock’s market cap is $44.01 million. AVEO Pharmaceuticals has a 12-month low of $0.50 and a 12-month high of $1.15.

In other AVEO Pharmaceuticals news, major shareholder Equity Opportunities Iv Growth purchased 6,000,000 shares of the company’s stock in a transaction on Tuesday, March 28th. The shares were purchased at an average cost of $0.50 per share, for a total transaction of $3,000,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 5.10% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of AVEO. Sarissa Capital Management LP acquired a new stake in shares of AVEO Pharmaceuticals during the fourth quarter valued at approximately $917,000. New Leaf Venture Partners L.L.C. bought a new stake in AVEO Pharmaceuticals during the fourth quarter valued at about $1,399,000. Renaissance Technologies LLC increased its stake in AVEO Pharmaceuticals by 5.7% in the fourth quarter. Renaissance Technologies LLC now owns 2,743,900 shares of the biopharmaceutical company’s stock valued at $1,482,000 after buying an additional 148,500 shares during the last quarter. Finally, Perceptive Advisors LLC bought a new stake in AVEO Pharmaceuticals during the fourth quarter valued at about $1,678,000. Hedge funds and other institutional investors own 37.94% of the company’s stock.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

5 Day Chart for NASDAQ:AVEO

Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.